Lido Advisors LLC Takes $364,000 Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Lido Advisors LLC acquired a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 27,487 shares of the company’s stock, valued at approximately $364,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Summit Global Investments boosted its holdings in shares of Takeda Pharmaceutical by 75.5% in the fourth quarter. Summit Global Investments now owns 729,200 shares of the company’s stock valued at $9,655,000 after acquiring an additional 313,642 shares in the last quarter. Northern Trust Corp increased its position in shares of Takeda Pharmaceutical by 14.6% during the 4th quarter. Northern Trust Corp now owns 1,873,588 shares of the company’s stock valued at $24,806,000 after purchasing an additional 238,161 shares during the period. Crossmark Global Holdings Inc. raised its stake in shares of Takeda Pharmaceutical by 284.9% in the 4th quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock worth $2,787,000 after buying an additional 155,795 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at $1,447,000. Finally, Marshall Wace LLP bought a new position in Takeda Pharmaceutical during the fourth quarter valued at about $1,010,000. Institutional investors own 9.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

NYSE TAK opened at $15.38 on Tuesday. The stock has a market capitalization of $48.94 billion, a P/E ratio of 38.45, a P/E/G ratio of 0.24 and a beta of 0.26. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The business’s fifty day moving average is $14.86 and its two-hundred day moving average is $13.98. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.43.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.